The tablets are a new formulation of the drug lorcaserin, which is intended to help patients achieve and maintain weight loss when paired with a reduced-calorie diet and increased physical activity.
Arena, which entered into a licensing agreement with Tokyo-based Eisai in 2010, will receive a $10 million milestone payment for the approval.
Belviq XR is expected to reach the market in fall 2016.
More articles on the drug market:
PhRMA adds 5 new companies to its ranks, including generic rival Teva
Roche’s blood cancer drug disappoints in clinical trial
FDA approves Aurobindo’s new pain med
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
